Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.56 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901787 | 0.88 | CYP4F2 (0.56) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL6913578 | 0.86 | CYP4F2 (0.61) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL901639 | 0.86 | CYP4F2 (0.61) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL8257852 | 0.85 | CYP4F2 (0.59) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL2347025 | 0.84 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL12723403 | 0.82 | CYP4F2 (0.56) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL11247614 | 0.82 | CYP4F2 (0.56) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL7520208 | 0.82 | CYP4F2 (0.56) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL12984627 | 0.82 | CYP4F2 (0.56) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A | |
| SCHEMBL8364365 | 0.82 | CYP4F2 (0.59) | CYP4F2CYP4A11CYP4Z1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513084-B1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| CN-103328479-A | 7-hydroxy-pyrazolo [1,5-a ] pyrimidine compounds and their use as CCR2 receptor antagonists | PROXIMAGEN LTD | 2013-09-25 | — | — | CN | disclosed |
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2621928-A1 | 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| EP-2513084-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012041817-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011073160-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | CYP4F2 3240/4885CYP4A11 3300/4885CYP4Z1 3600/4885 |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | CYP4F2 3240/4885CYP4A11 3300/4885CYP4Z1 3600/4885 |
| US-20130252951-A1 | 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR5, CCR1 | CYP4F2 1184/4885CYP4A11 639/4885CYP4Z1 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.